Related Experiment Video
Updated: Dec 9, 2025
Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma
Published on: September 8, 2021
Potential predictive value of SCN4A mutation status for immune checkpoint inhibitors in melanoma
Weiyin Lin1, Anqi Lin1, Zhefu Li2
1Department of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, People's Republic of China.
Abstract:
Melanoma refers to a pigmented nevus with malignant changes. The preferred treatment for primary melanoma is surgical excision and postoperative radiotherapy, but the prognosis is poor. Immune checkpoint inhibitors (ICIs) have been remarkably successful in different types of cancers, but not all cancer patients can benefit from it. Therefore, it is essential to find predictable biomarkers and improve the accuracy of treatment. In this study, we used survival analysis, gene panorama analysis, immune cell enrichment analysis, TMB analysis, and GSEA to demonstrate that SCN4A gene mutations may be used as one of the indicators to predict the prognosis of melanoma patients undergoing ICI treatment. The research further indicates that SCN4A gene mutations improve the prognosis of ICI treatment. It is hoped that the effect of SCN4A on immunogenicity and tumor immunity can be demonstrated to further suggest the effect of this gene on the efficacy of ICIs.
Insights
SCN4A gene mutations may predict melanoma patient prognosis during immune checkpoint inhibitor (ICI) treatment. These mutations appear to improve outcomes, suggesting SCN4A as a potential biomarker for enhancing ICI therapy effectiveness.
Area of Science:
- Oncology
- Genetics
- Immunotherapy
Background:
- Melanoma, a malignant skin cancer, often has a poor prognosis despite standard treatments like surgery and radiotherapy.
- Immune checkpoint inhibitors (ICIs) have advanced cancer therapy, but patient response varies, necessitating predictive biomarkers.
- Identifying reliable biomarkers is crucial for improving treatment accuracy and patient outcomes in melanoma.
Purpose of the Study:
- To investigate the potential of SCN4A gene mutations as a predictive biomarker for melanoma patients receiving ICI treatment.
- To determine if SCN4A gene mutations correlate with improved prognosis in melanoma patients undergoing immunotherapy.
- To explore the role of SCN4A in tumor immunogenicity and its impact on ICI efficacy.
Main Methods:
- Survival analysis to assess prognostic significance.
- Gene panorama analysis for comprehensive genetic insights.
- Immune cell enrichment and tumor mutational burden (TMB) analysis.
- Gene Set Enrichment Analysis (GSEA) to explore molecular pathways.
Main Results:
- SCN4A gene mutations were identified as a potential indicator for predicting melanoma patient prognosis.
- The study indicated that SCN4A gene mutations are associated with an improved prognosis in patients treated with ICIs.
- Preliminary findings suggest a link between SCN4A mutations and enhanced tumor immunity.
Conclusions:
- SCN4A gene mutations may serve as a predictive biomarker for melanoma patients undergoing ICI therapy.
- SCN4A mutations show potential for improving the efficacy of immune checkpoint inhibitor treatments.
- Further research into SCN4A's influence on immunogenicity and tumor immunity is warranted to fully elucidate its role in ICI response.
